quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 24, 2026

Why Most AI Projects Will Fail — And How to Find the Companies That Won't

View original at nasdaq.com
Why Most AI Projects Will Fail — And How to Find the Companies That Won't In this episode of Motley Fool Hidden Gems Investing, Motley Fool contributor Rachel Warren sits down with Steve Lucas, chairman and CEO of Boomi, to unpack what Wall Street is missing: Why the next wave of AI winners won't be the flashy model ma…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The four major U.S. hyperscalers spent around $400-410 billion on AI capex last year, rising to over $700 billion this year

    60% confidence
  • A $1,000 investment in Netflix at the time of its Stock Advisor recommendation on December 17, 2004 would be worth $369,577

    60% confidence
  • Stock Advisor's total average return is 908%, compared to 208% for the S&P 500

    60% confidence
  • AI is meaningless without data, and unique proprietary data is what investors should look for

    60% confidence
  • Companies citing AI efficiency as the reason for layoffs are often engaging in spin without real data to back up productivity claims

    60% confidence
  • Gartner forecasts that a number of agentic AI projects will fail or fail to return results and will be shut down by the end of 2027

    60% confidence
  • New customer/logo acquisition is the number one indicator of a sufficiently transformative technology

    60% confidence
  • Claims that AI will take away human jobs are largely nonsense and fraud designed to scare people into buying a product

    60% confidence
  • Nvidia is the one company unequivocally making a ton of money from AI, while many other companies build amazing models but lose extraordinary amounts of money

    60% confidence
  • A $1,000 investment in Nvidia at the time of its Stock Advisor recommendation on April 15, 2005 would be worth $1,301,557

    60% confidence
  • The cost to train GPT-2 was just shy of $50,000

    60% confidence
  • Steve Lucas previously turned Marketo into a $4.75 billion acquisition by Adobe

    60% confidence
  • The cost to train frontier AI models in 2026 exceeds $1 billion

    60% confidence
  • As many as 40% of enterprise AI projects could ultimately be abandoned

    60% confidence
  • ROI now supersedes AI as the priority for boards and executives evaluating AI investments

    60% confidence
  • OpenAI is burning $3 billion a month, which is a reported and reliable figure

    60% confidence
  • Elon Musk put a cap on what his employees can spend at Tesla and SpaceX, per a recently reported news item

    60% confidence
  • If humans don't trust something, it will never be used, and this applies to AI just as it did to prior data and analytics projects

    60% confidence
  • Within the next two decades, AI will largely manage or solve the major health challenges humans currently face, including curing type 1 diabetes

    60% confidence

Data points we hold from this source

OpenAI · cash burn rate3 billion_USD_per_month
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Why Most AI Projects Will Fail — And How to Find the Companies That Won't — Source | Via News | pt.VIA.NEWS